卢元珺，理学博士，副研究员，硕士生导师，先后于中南大学获得学士与硕士学位，并于香港大学取得博士学位。主要研究方向为肝癌耐药的分子机制，并积极探索肿瘤靶向治疗的新策略。在Molecular Cancer, Drug Resistance Updates等国际高水平期刊发表论文20余篇。
基金项目
1. 自然科学基金-青年项目， 2026-2028，30万，主持
2. 四川省科技厅港澳台科技创新合作项目，2024-2025，20万，主持
3. 四川省肿瘤医院优秀青年基金，2024-2025，10万，主持
代表性学术成果
1. Yuanjun Lu, Shuoshuo Ma, Yau-Tuen Chan, Ya Wu, Yibin Feng, Ning Wang*. Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements [J]. Journal of Advanced Research, 2025. (IF=13.0)
2. Yau-Tuen Chan, Junyu Wu, Yuanjun Lu, Qiucheng Li, Zixin Feng, Lin Xu, Hongchao Yuan, Tingyuan Xing, Cheng Zhang, Hor-Yue Tan, Yibin Feng, Ning Wang*. Loss of LncRNA LINC01056 leads to sorafenib resistance in HCC [J]. Molecular cancer, 2024, 23(1): 74. (IF=33.9)
3. Junyu Wu, Hor-Yue Tan, Yau-Tuen Chan, Yuanjun Lu, Zixin Feng, Hongchao Yuan, Cheng Zhang, Yibin Feng, Ning Wang*. PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer[J]. Journal of Experimental & Clinical Cancer Research, 2024, 43(1): 42. (IF=12.8)
4. Yuanjun Lu, Yau-Tuen Chan, Junyu Wu, Zixin Feng, Hongchao Yuan, Qiucheng Li, Tingyuan Xing, Lin Xu, Cheng Zhang, Hor-Yue Tan, Terence Kin-Wah Lee, Yibin Feng, Ning Wang*. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress[J]. Drug Resistance Updates, 2023, 71: 101015. (IF=21.7)
5. Yuanjun Lu#, Yazhou Liu#, Junjie Lan, Yau-Tuen Chan, Zixin Feng, Lan Huang, Ning Wang*, Weidong Pan*, Yibin Feng*. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma[J]. Journal of Advanced Research, 2023, 51: 181-196. (IF=13.0)
6. Yuanjun Lu, Yau-Tuen Chan, Hor-Yue Tan, Cheng Zhang, Wei Guo, Yu Xu, Rakesh Sharma, Zhe-Sheng Chen, Yi-Chao Zheng, Ning Wang*, Yibin Feng*. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 1-17. (IF=12.8)
7. Yuanjun Lu, Yau-Tuen Chan, Hor-Yue Tan, Sha Li, Ning Wang*, Yibin Feng*. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy[J]. Molecular cancer, 2020, 19: 1-16. (IF=33.9)
8. Yuanjun Lu, Hor-Yue Tan, Ning Wang*, Yibin Feng*. Polarization of Tumor-Associated Macrophages by Chinese Medicine Intervention: Mechanisms and Applications[M]//Macrophage Activation-Biology and Disease. IntechOpen, 2019.
9. Yau-Tuen Chan, Yuanjun Lu, Junyu Wu, Cheng Zhang, Hor-Yue Tan, Zhaoxiang Bian, Ning Wang*, Yibin Feng*. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives[J]. Theranostics, 2022, 12(7): 3329. (IF=13.3)
10. Ning Wang, Hor-Yue Tan, Yuanjun Lu, Yau-Tuen Chan, Di Wang, Wei Guo, Yu Xu, Cheng Zhang, Feiyu Chen, Guoyi Tang, Yibin Feng*. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 86. (IF= 52.7)
